Tate & Lyle PLC
18 December 2006 - Tate & Lyle PLC
2007 CALENDAR YEAR PRICING ROUNDS
Tate & Lyle issues the following routine update regarding the 2007 calendar year
pricing rounds.
Food & Industrial Ingredients, Americas has substantially completed the
negotiation of its 2007 calendar year sales contracts. There was a small loss in
sweetener volume as it sought to increase margins in a rising corn market at the
end of the negotiating period. Total sweetener margins for the 2007 calendar
year are expected to be higher, much as anticipated. We also anticipate
achieving higher total net margins on both value added food and industrial
ingredients.
Our expectations for margins on ethanol sales, which represent a small
proportion of Food & Industrial Ingredients, Americas' overall sales, remain
consistent with our assumptions for our new facility in Fort Dodge, Iowa. Higher
corn costs and lower gasoline prices mean that 2007 ethanol margins are expected
to be substantially lower than those achieved in the current financial year.
Recent comments from the EU Agriculture Commissioner regarding the slow
surrender of quota to the restructuring fund have heightened concerns over a
continuation of oversupply of sugar in the sugar year ending 30 September 2008.
Against this background, we now think it unlikely that any recovery in sugar
pricing will occur during the 2007 calendar year. This reinforces our decision
to surrender beet sugar quota at Eastern Sugar, where negotiations are ongoing.
The pricing round for Food & Industrial Ingredients, Europe is (as is normal for
this time of year) at an early stage. So far satisfactory progress is being made
to recover higher raw material and energy costs.
-0-
*T
CONTACTS
Ferne Hudson, Head of Media and Press Relations
Tel: 020 7626 6525 or Mobile 07713 067433
Mark Robinson, Director of Investor Relations
Tel: 020 7626 6525 or Mobile: 07793 515861 investorrelations@tateandlyle.com
*T
About Tate & Lyle: Tate & Lyle is a world leading manufacturer of renewable food
and industrial ingredients. It uses innovative technology to transform corn,
wheat and sugar into value-added ingredients for customers in the food,
beverage, pharmaceutical, cosmetic, paper, packaging and building industries.
The Company is a leader in cereal sweeteners and starches, sugar refining, value
added food and industrial ingredients, and citric acid. Tate & Lyle is the world
number-one in industrial starches and is the sole manufacturer of SPLENDA(R)
Sucralose.
Headquartered in London, Tate & Lyle is listed on the London Stock Exchange
under the symbol TATE.L. In the US its ADRs trade under TATYY. The Company
operates more than 65 production facilities in 29 countries, throughout Europe,
the Americas and South East Asia. It employs 7,000 people in its subsidiaries
with a further 4,800 employed in joint ventures. Sales in the year to 31 March
2006 totalled £3.7 billion. Additional information can be found on this website
www.tateandlyle.com.
SPLENDA(R) and the SPLENDA(R) logo are trademarks of McNeil Nutritionals, LLC
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.